Ken Griffin Icosavax, Inc. Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$5.95 - $15.79 $7.9 Million - $21 Million	-1,326,993 Reduced 82.79%	275,779 $4.35 Million
Q3 2023 Nov 14, 2023	SELL	$7.22 - $10.05 $4.2 Million - $5.85 Million	-582,238 Reduced 26.65%	1,602,772 $12.4 Million
Q2 2023 Aug 14, 2023	BUY	$4.89 - $10.57 $3.02 Million - $6.52 Million	617,302 Added 39.38%	2,185,010 $21.7 Million
Q1 2023 May 15, 2023	SELL	$5.62 - $11.51 $15,859 - $32,481	-2,822 Reduced 0.18%	1,567,708 $9.09 Million
Q4 2022 Feb 14, 2023	SELL	$2.32 - $10.97 $285,833 - $1.35 Million	-123,204 Reduced 7.27%	1,570,530 $12.5 Million
Q3 2022 Nov 14, 2022	BUY	$3.09 - $9.21 $389,420 - $1.16 Million	126,026 Added 8.04%	1,693,734 $5.35 Million

1.37M

Ticker ICVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,885,200
Description
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical tri...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.